In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
Authors:
- Jacinda C. Abdul-MutakabbirJacinda C. Abdul-Mutakabbir
- Juwon YimJYJuwon Yim
- Logan NguyenLNLogan Nguyen
- Philip T. MaassenPMPhilip T. Maassen
- Kyle StamperKSKyle Stamper
- Zain ShiekhZSZain Shiekh
- Razieh KebriaeiRKRazieh Kebriaei
- Ryan K. ShieldsRSRyan K. Shields
- Mariana CastanheiraMCMariana Castanheira
- Keith S. KayeKKKeith S. Kaye
- Michael J. RybakMRMichael J. Rybak
Open Access
- 20 July 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (7) , 880
Abstract
Acinetobacter baumannii is currently classified as one of six pathogens that contribute to increased patient mortality. Thus, exploratory studies navigating alternative treatment strategies are of supreme interest. Herein, we completed minimum inhibitory concentration (MIC) testing, and time-kill analyses (TKA) on 50 carbapenem-resistant Acinetobacterbaumannii isolates including 28 colistin-resistant isolates. Upon testing of MEM or TGC in the presence of sub-inhibitory COL against the 50 isolates, there was a median 2-fold reduction in MEM and TGC MICs. In the TKAs, the COL+MEM combination was synergistic in 45 (90%) isolates and bactericidal in 43 (86%) isolates at 24 hours, whereas the COL+TGC combination TKAs demonstrated synergy in 32 (64%) isolates and bactericidal activity was shown in 28 (56%) isolates. Additionally, sulbactam (SUL) and TGC were added to the COL+MEM dual therapy regimen to assess the possible utility of a triple therapy regimen against five non-responsive isolates. The COL+MEM+SUL and COL+MEM+TGC regimens effectively restored synergy in (5/5) 100% of the isolates. The results of this study demonstrate the potential utility of COL combinations in the treatment of carbapenem-resistant isolates.Keywords
This publication has 41 references indexed in Scilit:
- Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2011
- Carbapenems: Past, Present, and FutureAntimicrobial Agents and Chemotherapy, 2011
- Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patientsBMC Infectious Diseases, 2011
- Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patientsAnnals of Intensive Care, 2011
- Multiresistant Acinetobacter baumannii infections: epidemiology and managementCurrent Opinion in Infectious Diseases, 2010
- Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component SystemAntimicrobial Agents and Chemotherapy, 2009
- Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in PennsylvaniaAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activity of Tigecycline against Multidrug-Resistant Acinetobacter baumannii and Selection of Tigecycline-Amikacin SynergyAntimicrobial Agents and Chemotherapy, 2008
- Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled studyClinical Therapeutics, 2008
- Meropenem Clinical PharmacokineticsClinical Pharmacokinetics, 1995